Melanoma's hidden act

Researchers at the University of Bonn and the Johannes Gutenberg University Mainz have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens.¹ The group now is trying to circumvent this resistance mechanism and thinks doing so could improve treatment responses for current T cell therapy protocols.

Adoptive T cell transfer is one of three immunotherapy-based strategies used to treat metastatic melanomas and typically is used in patients for whom standard treatments have failed...